Search

Your search keyword '"Willekens, Christophe"' showing total 35 results

Search Constraints

Start Over You searched for: Author "Willekens, Christophe" Remove constraint Author: "Willekens, Christophe" Search Limiters Academic (Peer-Reviewed) Journals Remove constraint Search Limiters: Academic (Peer-Reviewed) Journals
35 results on '"Willekens, Christophe"'

Search Results

1. Immunomodulators for immunocompromised patients hospitalized for COVID-19: a meta-analysis of randomized controlled trials

2. RAS mutations in myeloid malignancies: revisiting old questions with novel insights and therapeutic perspectives.

3. Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort

4. Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia

5. Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers

6. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

7. Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib

8. When monoclonal gammopathy‐associated chronic neutrophilic leukemia is a reactive process distinct from a clonal myeloproliferative neoplasm: Lessons from mistakes.

9. Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia

12. RBD- specific Th1 responses are associated with vaccine-induced protection against SARS-CoV-2 infection in patients with hematological malignancies.

17. Low dose IL-2 in patients with steroid-dependent dysimmune manifestations associated with myelodysplastic syndromes: a three-case report.

18. Attenuated cytarabine, etoposide, dexamethasone plus rituximab (R‐Mini‐CYVE) regimen for patients with relapsed or refractory B‐cell non–Hodgkin's lymphoma not eligible for intensive chemotherapy.

19. Fulminant hemophagocytic lymphohistiocytosis induced by pandemic A (H1N1) influenza: a case report

20. Impact and consequences of intensive chemotherapy on intestinal barrier and microbiota in acute myeloid leukemia: the role of mucosal strengthening.

21. First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia.

22. High‐dose cyclophosphamide for hard‐to‐treat patients with relapsed or refractory B‐cell non‐Hodgkin's lymphoma, a phase II result.

23. Retroperitoneal fibrosis as extramedullary hematopoiesis of a chronic myelomonocytic leukemia.

24. IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives.

25. An Unusual Case of Constitutional Mismatch Repair Deficiency Syndrome With Anaplastic Ganglioglioma, Colonic Adenocarcinoma, Osteosarcoma, Acute Myeloid Leukemia, and Signs of Neurofibromatosis Type 1: Case Report.

26. Invasive cutaneous infection due to Scopulariopsis brevicaulis unsuccessfully treated with high-dose micafungin in a neutropenic patient.

27. Fulminant hemophagocytic lymphohistiocytosis induced by pandemic A (H1N1) influenza: a case report.

28. Identification of a New Mutation on the β-Globin Gene: Codons 8/9 (+AGAA); GAG.AAG.TCT(Glu-Lys-Ser)>GAG. AA AGAAG, in a Patient From the North of France with a Phenotype of β-Thalassemia Minor.

29. A miR-150/TET3 pathway regulates the generation of mouse and human non-classical monocyte subset.

30. The Impact of Risk-adapted Treatment Strategy on Outcome of Patients with Acute Myeloid Leukemia Aged ≥ 60 Years after Allogeneic Stem Cell Transplant.

32. Bone marrow necrosis: a culture medium for bacteria.

33. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.

34. Concurrent Etoposide, Steroid, High-dose Ara-C and Platinum chemotherapy with radiation therapy in localised extranodal natural killer (NK)/T-cell lymphoma, nasal type.

35. ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia.

Catalog

Books, media, physical & digital resources